Methoxyethyl Etomidate Hydrochloride (ET‐26): A Phase I Clinical Trial Assessing Drug–Drug Interactions in Healthy Subjects.

Methoxyethyl etomidate hydrochloride (ET‐26) is a novel intravenous general anesthetic designed to address the clinical limitations of etomidate. This Phase I clinical trial assessed the pharmacokinetics, pharmacodynamics, drug–drug interaction (DDI) potential, and safety of ET‐26 in 68 healthy subj...

Descripción completa

Detalles Bibliográficos
Publicado en:Journal of Clinical Pharmacology Vol. 65; no. 11; pp. 1443 - 1451
Autores principales: Yang, Fan, Ye, Pan‐Pan, Lv, Wen‐Shuo, Li, Li‐Ze, Zhao, Bao‐Zhong, van denAnker, John, Yang, Xin‐Mei, Song, Lin‐Lin, Yang, Xiao‐Ran, Zheng, Yi, Ke, Bo‐Wen, Zhao, Wei
Formato: clinical trial research tables/charts Journal Article
Publicado: Wiley-Blackwell Nov2025
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=188898504&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 188898504
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        00912700
        5WH
      jtl: Journal of Clinical Pharmacology
      issn: 00912700
      maglogo: Y
    pubinfo:
      dt: Nov2025
      vid: 65
      iid: 11
      pid: 480
      pub: Wiley-Blackwell
      place: Malden, Massachusetts
    artinfo:
      ui:
        188898504
        186332001
        188898504
        188898504
        10.1002/jcph.70071
        188898504
      ppf: 1443
      ppct: 8
      formats:
      tig:
        atl: Methoxyethyl Etomidate Hydrochloride (ET‐26): A Phase I Clinical Trial Assessing Drug–Drug Interactions in Healthy Subjects.
      aug:
        au:
          Yang, Fan
          Ye, Pan‐Pan
          Lv, Wen‐Shuo
          Li, Li‐Ze
          Zhao, Bao‐Zhong
          van denAnker, John
          Yang, Xin‐Mei
          Song, Lin‐Lin
          Yang, Xiao‐Ran
          Zheng, Yi
          Ke, Bo‐Wen
          Zhao, Wei
        affil: Department of Clinical Pharmacy, Institute of Clinical Pharmacology, Key Laboratory of Chemical Biology (Ministry of Education), NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drug, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, China
      sug:
        subj:
          Etomidate Administration and Dosage
          Drug Interactions Evaluation
          Etomidate Pharmacokinetics
          Etomidate Pharmacodynamics
          Patient Safety Evaluation
          Human
          Clinical Trials
          Adolescence
          Adult
          Rifampin Administration and Dosage
          Fluconazole Administration and Dosage
          Omeprazole Administration and Dosage
          Midazolam Administration and Dosage
          Adverse Drug Event Risk Factors
          China
          Descriptive Statistics
          Confidence Intervals
          Treatment Related Pain Risk Factors
          Injection Sites
          Myoclonus Risk Factors
          Male
          Female
          Body Mass Index
          ROC Curve
          Data Analysis Software
          Funding Source
          Adolescent: 13-18 years
          Adult: 19-44 years
          Male
          Female
      ab: Methoxyethyl etomidate hydrochloride (ET‐26) is a novel intravenous general anesthetic designed to address the clinical limitations of etomidate. This Phase I clinical trial assessed the pharmacokinetics, pharmacodynamics, drug–drug interaction (DDI) potential, and safety of ET‐26 in 68 healthy subjects across three sequences, evaluating interactions with rifampin (CYP2C19/3A4 inducer), fluconazole (CYP2C19/3A4 inhibitor), and omeprazole/midazolam. ET‐26 pharmacokinetic analyses showed that compared with administration of ET‐26 alone, co‐administration of rifampin resulted in a 10% decrease in the geometric mean ratio (GMR) of the AUC0‐∞ for ET‐26 (GMR 90.0%, 90% CI 85.4%‐94.8%), while co‐administration fluconazole increased the AUC0‐∞ by 18.5% (GMR 118.5%, 90% CI 111.4%‐126.2%). ET‐26 slightly increased the AUC0‐∞ by 18.5% for omeprazole (GMR 118.5%, 90% CI 111.4%‐126.1%) and 11.1% for midazolam (GMR 111.1%, 90% CI 104.9%‐117.8%). The 90% CI for key parameters largely fell within no‐effect boundaries, indicating no clinically significant DDIs. Pharmacodynamic assessments showed consistent sedation profiles across sequences, with mild additive effects with midazolam. Safety evaluations identified treatment‐emergent adverse events such as injection site pain and myoclonus, more frequent with fluconazole. No serious adverse events were observed. These findings suggest ET‐26 exhibits a favorable safety and pharmacokinetic profile with no significant DDIs observed in clinical, supporting its potential as a safer alternative to etomidate for general anesthesia.
      pubtype: Academic Journal
      doctype:
        clinical trial
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N